DNER and acute myeloid leukemia: BET proteins promote aberrant expression of the MYC oncogene in various hematologic malignancies such as mixed-lineage leukemia, acute myeloid leukemia (AML), Burkitt's lymphoma and Burkitt-like lymphoma; in these cells, disruption of BET binding significantly reduces cellular proliferation and induces apoptosis [24–28].